Abstract. China is a country with a high incidence of gastric cancer (GC), where the GC incidence and the resultant mortality rates account for 50% of those worldwide.
Introduction
Of the worldwide population of patients with gastric cancer (GC), ~42% of the men and 19% of the women are Chinese, and the number of patients suffering from GC has increased in recent years (1, 2) . Although significant progress has been made in the comprehensive treatment with surgery, the prognosis for postoperative patients with GC remains poor (3) . A detailed understanding of GC occurrence and development, and the factors that influence its prognosis are required.
The barrier-to-autointegration factor 1 (BANF1) family of proteins has a variety of functions associated with the maintenance of the intact cellular genome (4) . BANF1 is an ~10-kDa, highly conserved DNA-binding protein that forms homodimers. It was first identified during the combination of a retrovirus and host, promoting the fusion of retroviruses and target genes in vitro (5) . As an important part of the lamina, BANF1 has essential interactions with numerous cellular proteins, including transcription factors and DNA damage repair proteins (6, 7) . It regulates gene expression, participates in the formation of karyotin structures and is associated with cell mitosis (8) .
In recent years, with the advent of microarray technology, novel ideas and insights into the diagnosis and treatment of tumors have been proposed (9) . To understand the effect of BANF1 on GC progression, its mRNA and protein expression levels in the gastric tumor tissue were compared with that in adjacent non-tumorous tissue. BANF1 expression was demonstrated to be upregulated in patients with GC. In addition, a high expression of BANF1 was identified as a poor prognostic factor. Furthermore, BANF1 expression correlated with patient age, tumor differentiation and infiltration depth. Therefore, BANF1 may be an oncogene. The results of the present study may aid in developing a reference in prognostic evaluation of patients with GC. After the diluted anti-BANF1 antibodies were preincubated with (+) and without (-) 0.5 mM anti-BANF1-peptide-specific antibodies for 2 h at RT, they were used to determine BANF1 expression in SGC-7901 and MNK-45 GC cells (11) . The aforementioned western blotting protocol was performed in the same way following this incubation.
Barrier-to-autointegration
Immunohistochemistry. Tissue specimens were cut into successive 4 µm-thick sections. Then, antigen retrieval was performed by heating the specimens using the pressure cooker antigen repairing method at 120˚C, followed by washing with xylene and gradual rehydration with a descending ethanol series. Endogenous peroxidase activity in the specimens was neutralized via incubation with 3% hydrogen peroxide for 5 min at room temperature. Subsequently, the specimens were incubated in 5% bovine serum albumin (cat. no. A8020; Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 30 min at RT to block nonspecific binding. Then, the tissues were incubated with rabbit monoclonal anti-BANF1 antibody (1:100) overnight at 4˚C. Following incubation with the horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibodies (cat. no. WLA023a; 1:500; Wanleibio Co., Ltd.) for 1 h at RT, all sections were visualized using 3,3'-diaminobenzidine, and the slides were counterstained with haematoxylin (cat. no. WLA051a; Wanleibio Co., Ltd.) for 1 min at RT (1,2). The coverslips were then mounted with anti-fade mounting medium and observed under a microscope (magnification x200; Olympus DP73; Japan).
Staining intensity score. The BANF1 expression-intensity scores were determined by two independent observers blinded to the clinicopathological data of patients. In order to calculate the percentage of BANF1-positive cells, 100 cells were randomly selected and counted in five representative fields of each section. The positive expression area was counted as follows: <5%, score of 0; <30%, score of 1; 30-70%, score of 2; and >70%, score of 3. The staining intensity score was graded as follows: Colourless, 0; weak, 1; intermediate, 2; and strong, 3. The positive expression area and staining intensity scores were multiplied (2).
Statistical analysis. All data were analysed with the SPSS 20.0 software program (IBM Corp., Armonk, NY, USA). Results were expressed as the mean ± standard deviation. Student's t-tests were performed to evaluate the differences in BANF1 mRNA expression between the gastric tumor and normal tissues. The Spearman's rank correlation coefficient test was used to analyze the correlation between BANF1 expression and clinicopathological features. The Mann-Whitney U-test was used to calculate the statistical significance. Survival curves were derived using the K-M estimator method and compared using the log-rank test. Cox's proportional hazards model was used to analyze the effect of clinicopathological parameters on patient survival. P<0.05 was considered to indicate a statistically significant difference.
Results
High expression of BANF1 mRNA in GC tissues. In the GSE54129 data sets, BANF1 expression in the gastric tumor tissues was identified to be significantly higher compared with in the adjacent non-tumorous tissues ( Fig. 1) , as demonstrated by statistical parameters for the BANF1 gene expression profiles in Table II (P=1.50x10 -87 ).
Expression of BANF1 in GC cells. After the diluted anti-BANF1 antibodies were preincubated with the anti-BANF1-peptide-specific antibodies, the latter were used for western blotting. Examination of total extracts of SGC-7901 and MNK-45 GC cells by immunoblotting revealed that the antibodies specifically recognized a 10-kDa protein (Fig. 2, lanes 1 and 2) , which was not present at the same positions in the lanes with anti-BANF1-peptide-specific antibody preincubation (Fig. 2, lanes 3 and 4) . This indicates that Table I . Association between BANF1 expression and clinicopathological features. BANF1 protein is expressed in SGC-7901 and MNK-45 GC cells and the anti-BANF1 antibody can specifically recognize the 10 kDa BANF1 protein.
Difference in BANF1 protein expression between the normal and gastric tumor tissues. The intensity of BANF1 expression in the nucleus of GC cells varied (Fig. 3) . The total of 118 GC tissues included three cases of negative BANF1 expression, eight weakly positive (+) samples, 42 moderately positive (++) samples and 65 strongly positive (+++) samples. By contrast, negative (-) and weakly positive (+) BANF1 staining was detected in 18 samples and five samples of 23 normal tissues, respectively, while no moderately positive or strongly positive staining was detected. The protein expression of BANF1 in GC specimens was significantly higher compared with that in normal tissues (P<0.001; Table III ). Table I . The rates of positive BANF1 expression in GC tissues with low, medium and high differentiation statuses were 100, 98 and 71.4%, respectively. The BANF1 expression in poorly differentiated GC tissues was significantly higher compared with that in moderately and highly differentiated tissues, and was associated with the differentiation degree of tumors (P<0.001). In addition, BANF1 expression correlated with the patient age (P=0.001) and tumor infiltration depth (P=0.011).
BANF1 expression is associated with patient age, and the degree of GC differentiation and depth of invasion. The immunohistochemistry results are summarized in

Effect of BANF1 expression on the overall survival (OS) of postoperative patients.
Online survival analysis was performed using the GC database in K-M Plotter, which revealed that the survival times for patients with high BANF1 mRNA expression was significantly reduced compared with that for the low-expression patients [log-rank test, P<0.001; hazard ratio (HR), 2.37; 95% confidence interval (CI), 1.93-2.92; Fig. 4A ]. Subsequently, the K-M estimator method was used to analyze the effect of BANF1 expression on the postoperative overall survival (OS) time of patients, the follow-up period was 150 months, and the mortality was considered as the end point during the follow-up period. The survival curve suggested that the OS of the patients with low BANF1 expression was significantly increased compared with the OS of high expression patients (log-rank test, P<0.001; Fig. 4B) . Thus, the level of BANF1 expression may be used as a prognostic indicate for patients with GC. Next, the age, the TNM stage and other clinical features were incorporated into the Cox regression model. It was revealed that the tumor differentiation status and the TNM stage were independent factors affecting the OS of patients with GC (Table IV) .
Discussion
The five-year survival rates of postoperative patients with GC vary between 15 and 60%, with GC diagnosis and detection lacking effective biomarkers (1, 12) . Despite the significant advances in the understanding of GC pathogenesis, there is no effective therapy available for GC treatment. Therefore, the identification of effective biomarkers is required to significantly improve the early diagnosis rate and prognosis for patients with GC. 
BANF1 expression -----------------------------------------------------------------------------------Group
No. BANF1 encodes a highly conserved BAF protein consisting of 89 amino acids and binding to double-stranded DNA with high-affinity. It was discovered due to its involvement in the integration of retroviral DNA (13) . Regulation of BAF phosphorylation, mediated by cell or virus, regulates numerous cellular activities, including protein dimerization, its binding to DNA, and subcellular localization of the protein (14) (15) (16) . Additionally, BAF participates in karyomi- (14) (15) (16) . Additionally, BAF participates in karyomi-(14-16). Additionally, BAF participates in karyomitosis, karyon assembly, karyoplasm regulation and the DNA damage response (17) . As the first protein that is recruited to the core area of karyolemma, the role of BAF in mitosis is important. Once BAF is located at the core of chromatin, other karyotheca anchoring and membrane-spanning proteins are recruited to complete the nuclear membrane reformation, which is a key step in cell mitosis (18, 19) . Previous studies have demonstrated that the absence of BAF or the blockage of its phosphorylation results in abnormal morphological abnormalities of the caryotheca (13) . This causes aberrant nuclear architecture and disrupts normal cell mitosis process (20) . Abnormal mitosis may cause chromosomal instability, which is considered a characteristic change in malignant tumor cells (21) .
BAF is able to positively or negatively regulate cell activities, although the specific mechanisms remain unclear. At the early stages of Caenorhabditis elegans embryogenesis, BAF regulates seam cell fusion by suppressing the expression of epithelial fusion failure-1-fused protein and the development of germ cells (22) . It has been reported that BAF inhibits transcription in vaccinia virus deficiency in the viral B1 kinase (23, 24) . Activation of BANF1 may inhibit skin inflammation in psoriatic lesions by inactivation of S100A9 and c-Jun, but it may also promote keratinocyte proliferation (5) . A coding mutation of the BANF1 alanine-12 to threonine was reported to be associated with BANF1-protein instability and abnormalities of the caryotheca, which has been confirmed as the hereditary fundamental of Néstor-Guillermo Progeria syndrome (NGPS) (25) . The disruption of the interaction between Prelamin A and BAF may be the cause of NGPS (26) . In addition, certain studies have reported that BANF1 expression is increased in breast and oesophageal cancer, and is associated with the poor prognosis of patients (27, 28) . Furthermore, its role is essential in regulating the S-phase process, stem cell self-renewal, and differentiation and proliferation of keratinocytes (5, 29) .
Targeted therapy and individualized tumor treatment are directed against specific gene mutations and proteins. Based on the notion of tumor therapy treatment, it is essential to identify suitable oncogenes to develop small molecules or monoclonal antibodies to control the disease. BANF1 has been demonstrated to be a target for the treatment of tumors with a specialized inhibitor aimed at BAF phosphorylation mediated by vaccinia related kinase 1, which blocks cell cycle progression in tumor cells by interfering with the caryomitotic phase (30) .
In the present study, the expression level of BANF1 was demonstrated to be significantly increased in GC tissues, and was inversely correlated with the patient age, tumor differentiation status and infiltration depth. Furthermore, the survival curve analysis revealed that the prognosis for patients with high BANF1 expression was poor at the mRNA and protein levels. To further investigate the association between the clinical characteristics and prognosis, Cox regression analysis was performed. The results suggested that tumor differentiation status and TNM stage were independent risk factors affecting the OS of patients with GC. The HR of BANF1 was 0.686 (95% CI, 0.305-1.542; P= 0.362) in the Cox regression analysis, but BANF1 significantly impacts poor survival of GC in the K-M analysis (log-rank P<0.001). This indicates that BANF1 has an impact on prognosis together with other factors, but is not an independent prognostic factor by itself. A limitation of the present study was that the BANF1 protein levels in the tissues from patients with GC were only detected by immunohistochemistry, and that western blot analysis is required to support the immunohistochemistry results.
In summary, BANF1 expression was upregulated in clinical GC tissues, and was associated with the tumor age, infiltration depth and differentiation. Additionally, the results of the present study confirmed that BANF1 closely correlates with adverse outcomes in GC patients undergoing surgery. Taken together, the present study is the first to propose that high BANF1 expression may be used as a novel indicator of poor prognosis or as a therapeutic target for patients with GC.
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